Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

CHMP recommends approval of Imlygic for unresectable melanoma

Oct. 26, 2015

Pembrolizumab active in patients with advanced biliary tract cancer

Oct. 22, 2015

Responses seen with avelumab in trials in mesothelioma, gastric/gastroesophageal junction cancer

Oct. 21, 2015

Kolltan Pharmaceuticals reports efficacy data from phase Ib KTN-3379 trial

Oct. 21, 2015

OMT and Armo BioSciences enter into anti-PD-1 antibody agreement

Oct. 21, 2015

Inotuzumab ozogamicin receives FDA breakthrough therapy designation for ALL

Oct. 20, 2015

Nordic Nanovector revises clinical development plan for Betalutin

Oct. 16, 2015

First-in-human results presented for personalized immunotherapy

Oct. 16, 2015

Enumeral anti-PD-1 and anti-TIM-3 antibodies may potentiate antitumor immune responses

Oct. 16, 2015

Incyte and Merck & Co. to study the combination of epacadostat with Keytruda

Oct. 14, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...